Sign up Australia
Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals osteoarthritis clinical trial ahead of schedule

The results readout for the study is expected during the December quarter this year.
folder saying clinical trial with stethoscope
It is estimated that the size of the osteoarthritis treatment market is US$5 billion per annum

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has recruited 80% of participants for its phase IIb clinical trial in knee osteoarthritis and bone marrow lesions.

This places the trial ahead of schedule with recruitment to be finalised over the coming month.

Importantly, this will allow for the pivotal results readout by the December quarter of 2018, a potential catalyst for the stock.

Shares were up almost 12% in early trade to 52.5 cents.

READ: Paradigm Biopharmaceuticals banking on near-term revenues from repurposing FDA approved drugs

The clinical trial will evaluate the effects of pentosan polysulfate sodium (PPS) on pain in participants with knee osteoarthritis and concurrent subchondral bone marrow lesions.

Injectable PPS has the potential to be a break-through in the treatment of osteoarthritis.

current therapies do not have adequate pain-relieving effects, provide no protection for the degenerating joint structures and are also associated with significant adverse side effects.

It is estimated that the size of the market is US$5 billion per annum.

TGA Special Access Scheme opens door to over 260 patients

260 osteoarthritis patients have now been treated by their doctors with PPS via the TGA Special Access Scheme.

This represents an almost doubling of the number of patients from six weeks ago showing real patient need for new osteoarthritis treatments.

Ross River clinical trial 75% recruited

Paradigm is also treating 24 patients with Ross River virus induced arthralgia (painful joints) as part of its phase IIa clinical trial of PPS injections.

The clinical trial is now over 75% recruited.

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

oil
July 13 2018
Zafar Karim, chief executive of Legendary Investments, talks to Proactive Investors about prospects for the group.
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use